Despite Uptake Barriers, Real-World Biosimilar Data Demonstrate Safety, Efficacy, Cost-Effectiveness
Presenters explored the real-world evidence in support of biosimilars at the Academy of Managed Care Pharmacy 2024 annual meeting. Biosimilars were a recurring subject at the Academy of Managed Care ...
Key messages Biosimilar-Enabled Access and Repositioning (BEAR) can unlock substantial value for patients, health systems and ...
When CVS Health finally revealed how it would provide follow-on versions of the blockbuster immunology drug Humira, it chose a different path than its peers. Rather than selecting several biosimilars ...
While the business case for biosimilars — generic equivalents of biologics, or medications made from living organisms — took ...
LONDON: The United Kingdom will miss out on savings worth hundreds of millions of pounds on off-patent medicines, an industry ...
Biosimilars provide cheaper alternatives to biologics, potentially reducing profitability for original drug makers. Long-lasting drug patents (up to 40.5 years) support sustained revenue for ...
Planegg-Martinsried, Germany, September 22, 2026 – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) announces the publication of the scientific article “From Reflection to Implementation – Tailored ...
DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the ...
Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, addressed attendees at the Association for Accessible Medicines' Access! annual meeting, held ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially ...
Please provide your email address to receive an email when new articles are posted on . The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results